Semaglutide vs. Tirzepatide: What the Trials Show

These are the two molecules the entire GLP-1 market runs on. They are related but not identical, and the trial evidence for each is specific enough that you can compare them on the numbers instead of the marketing. Here is what the studies actually report — and what that does and does not mean for a decision.

Different receptors, different design Semaglutide is a GLP-1 receptor agonist: it acts on a single incretin pathway to blunt appetite and slow gastric emptying. Tirzepatide is a dual agonist, acting on both the GIP and GLP-1 receptors. That mechanistic difference is the leading hypothesis for why tirzepatide has posted larger average weight reductions in its trials — though "larger on average" is a statement about study populations, not a promise for any individual.

The weight-loss numbers, side by side For semaglutide, the pivotal STEP-1 trial tested once-weekly semaglutide 2.4 mg in adults with overweight or obesity and reported a mean body-weight change of about −14.9%, versus roughly −2.4% for placebo, at 68 weeks[[cite:1]]. The approved dosing and titration schedule are laid out in the Wegovy prescribing information[[cite:2]].

For tirzepatide, the SURMOUNT-1 trial ran 72 weeks and reported mean reductions of roughly −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg³. Read across, the higher tirzepatide doses produced larger average weight loss than semaglutide did in its trial — but note these are separate studies with different designs, so the cleanest comparison comes from a head-to-head.

The one head-to-head trial SURPASS-2 compared tirzepatide directly against semaglutide 1 mg once weekly in adults with type 2 diabetes. Tirzepatide produced greater reductions in both A1c and body weight than semaglutide across its dose range[[cite:4]]. Two caveats keep this honest: SURPASS-2 studied a diabetes population, not a general weight-management one, and it used the 1 mg diabetes dose of semaglutide rather than the 2.4 mg weight-management dose. It is the best direct comparison available — and still not a perfect stand-in for the weight-loss question.

Side effects and tolerability Both molecules share the GLP-1 side-effect profile: nausea, diarrhea, constipation, and vomiting are the common ones, generally worst during dose escalation and easing as the body adjusts. Both carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, as the Wegovy labeling details for semaglutide[[cite:2]]. Tolerability is individual: the drug with the better average numbers is not automatically the one your body tolerates better.

So which one? The trials favor tirzepatide on average weight loss, and the single head-to-head favors it on both weight and glucose in a diabetes population. But "better in the aggregate" is not "better for you." The molecule you can actually access, afford at your maintenance dose, and tolerate week to week beats a slightly higher trial average you never reach. Decide the drug and the provider together — our [six-point checklist](/how-to-choose-a-glp1-provider) covers the provider side, and [what compounded GLP-1 costs per month](/what-compounded-glp1-costs-per-month) covers the money.

Bring it to a prescriber This is a starting point for a conversation, not a substitute for one. A licensed clinician who knows your history should make the call on molecule, dose, and monitoring. To see which providers offer both molecules with a full titration ladder, browse our [reviews](/research) and [comparisons](/compare).